Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 94

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 94
---
%
known as Evofuel Ltd.).                                 
Lavie Bio Ltd.               Israel         70.7% (4)(5)

(1)   The remaining 1.7% of AgPlenus Ltd.’s issued and outstanding share capital is held by AgPlenus’ former Chief Executive
                                 Officer and current director as a result of exercise of options.                           
----------------------------------------------------------------------------------------------------------------------------

(2)   The remaining 24.2% of Biomica Ltd.’s issued and outstanding share capital is held by: (i) SHC, who holds 22.7%, and (ii) Biomica's
       Chief Technology Officer, who holds 1.5%. For more information see “Item 4.B. Information on the Company—Business Overview—Market 
                                                 Segments—Human Health—Biomica Ltd.—Overview”.                                           
-----------------------------------------------------------------------------------------------------------------------------------------

(3)   The remaining 0.5% of Casterra Ag Ltd.’s issued and outstanding share capital is held by Casterra’s former employee as
                                                 a result of exercise of options.                                           
----------------------------------------------------------------------------------------------------------------------------

(4)        The remaining 29.3% of Lavie Bio Ltd.’s issued and outstanding share capital is held by (i) Pioneer Hi-Bred International,     
      Inc. (also known by the name Corteva), who holds 27.3%, and (ii) Lavie Bio’s former employees, who hold 2.0% as a result of exercise
                                                                  of options.                                                             
------------------------------------------------------------------------------------------------------------------------------------------

(5)                                       ICL (through an affiliate company) has an outstanding convertible                                    
      amount of approximately $10 million invested in Lavie Bio Ltd. under a SAFE agreement, which is convertible into shares of Lavie Bio Ltd.
                pursuant to the terms thereof. For more information see “Item 4.B. Information on the Company—Business Overview—Market         
                                                    Segments—Agriculture—Lavie Bio Ltd.—Overview”.                                             
-----------------------------------------------------------------------------------------------------------------------------------------------
D.          Property, Plants and Equipment
 
Our principal facility is located in Rehovot, Israel and consists of 1,870 square meters (approximately 20,129 square feet) of leased office space accommodating our corporate offices and our molecular, microbial and crop protection labs. The lease for this facility will expire December 31, 2027; however we have an option to extend it until December 31, 2030.
 
We perform most of our testing in plants, or in-planta